

Oregon Prescription Drug Monitoring Program 2018 4th Quarter Report

Percentage change evaluated relative to 4th Quarter, 2017


<http://www.orpdmp.com>



Summary

- Overall, queries increased 148%, including web, EDIE, and integrated queries.
- Increased registration among all prescriber types, pharmacists and delegates.
- Active use of the PDMP by registered prescribers increased in all prescriber groups.
- Prescriptions for opioids show a downward trend, while stimulants are rising.
- A sizable increase is observed in prescriptions for buprenorphine (25%) and buprenorphine/naloxone (27%).

Total OR PDMP Queries / Opioid Prescriptions by Month, 2018



Summary Statistics: October-December, 2018

Measure	Count	% Change*
Pharmacy Reporting	95%	-
Queries †	449,165	+47.2%
Healthcare providers	106,714	+31.8%
Pharmacies	179,248	+60.8%
Delegates	161,632	+44.1%

Special Requests: October-December, 2018

Measure	Count
Special Requests Total	102
Patient Records	14
Healthcare Board	82
Law Enforcement	6

* Percentage change figures evaluated relative to the same time period during the prior year.

† Query data drawn from Appriss AWARe for back compatibility with past reporting.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program 2018 4th Quarter Report

Percentage change evaluated relative to 4th Quarter, 2017

<http://www.orpdmp.com>



PDMP Enrollment and System Use: October-December, 2018

	Prescribers	Enrolled	Queried
All Prescribers	17,141	14,261 / 83.2 %	4,774 / 33.5 %
Top 4K Prescribers	4,000	3,752 / 93.8 %	1,867 / 49.8 %
Top 2K Prescribers	2,000	1,918 / 95.9 %	1,061 / 55.3 %

- During the 4th quarter there were 17,141 prescribers who wrote prescriptions for controlled substances in Oregon.
- Registration for the system has increased dramatically among all prescribers and especially among frequent prescribers reflecting the impact of mandatory registration.
- Use of the PDMP by enrolled prescribers remains relatively steady despite the influx of new registrants. In quarter four 33.5% of enrolled prescribers queried the system. This was down slightly from 38.6% at the close of quarter three, and down considerably from the same time the previous year. Many new registrants enrolled to comply with the mandate. Some of these new registrants are infrequent prescribers that may be less likely to use the system.

PDMP Query by User Group: October-December 2018

Discipline	Total User Accounts	% Change*	Active Users \pm †	% Change*	Average Queries per User \pm †
MD/PA/DO	16,003	+226%	3,156	+52%	23
Delegates	4,181	+53%	2,429	+57%	67
RPh	3,285	+23%	1,959	+21%	92
NP/CNS-PP	3,215	+119%	1,110	+53%	27
DDS/DMD	2,623	+194%	463	+82%	8
ND	523	+108%	169	+82%	11

- PDMP registration has increased among all prescriber groups, pharmacists and delegates.
- The number of registered users actively using the PDMP increased relative to the same quarter last year.
- Patterns of registration and use are likely driven by state mandated PDMP registration for prescribers and health IT integration efforts undertaken by health care systems.

* Percentage change figures evaluated relative to the same time period during the prior year.

\pm Users that have submitted a query this quarter.

† Query data drawn from Appriss AWAxR for back compatibility with past reporting.

Queries de-duplicated using last name, date of birth, prescriber ID and date of query.

Oregon Prescription Drug Monitoring Program 2018 4th Quarter Report

Percentage change evaluated relative to 4th Quarter, 2017

<http://www.orpdmp.com>



Top Prescriptions: October-December, 2018

Drug	# of Rx	% of all Rx	% Change*
All	1,486,861	100	-2.3
Hydrocodone	280,329	18.9	-10.4
Oxycodone	243,739	16.4	-5.6
Amphetamine	135,466	9.1	+16
Tramadol	88,286	5.9	-1.2
Lorazepam	84,602	5.7	-3.5
Zolpidem	78,947	5.3	-5.4
Pseudoephedrine	71,855	4.8	+9.1
Methylphenidate	68,357	4.6	+6.7
Alprazolam	67,996	4.6	-3.1
Clonazepam	65,194	4.4	-0.9

- The number of prescriptions for opioid and benzodiazepine medications continues to decrease relative to the same quarter last year.
- Prescriptions for stimulants, including amphetamine, methylphenidate and pseudoephedrine, increased relative to the same quarter last year.
- Stimulants Pseudoephedrine and methylphenidate have overtaken popular benzodiazepines alprazolam (Xanax) and clonazepam (Klonopin).

Prescriptions for Buprenorphine and Naloxone: October-December, 2018

Drug	# of Rx	% of all Rx	% Change*
Buprenorphine/Naloxone	30,249	2	+27.2
Buprenorphine	15,748	1.1	+24.7
Naloxone	2,195	0.1	-

- Prescriptions for buprenorphine and buprenorphine/naloxone combinations have increased dramatically relative to the same quarter last year.
- The apparent growing number of naloxone prescriptions may reflect increased reporting by pharmacies or an increase in naloxone co-prescription by clinicians or pharmacists.

Contact: PDMP Research Analyst, pdmp.research@state.or.us

* Percentage change figures evaluated relative to the same time period during the prior year